Romosozumab and renal function

Affiliations

¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, USA

Links

History

Received: 2022-06-01

Revised: 2022-06-29

Accepted: 2022-07-05

Cited Works (5)

Year	Entry
2020	McClung MR, Ebetino FH. History of risedronate. Bone. August 2020;137:115407.
2022	Miller PD, Adachi JD, Albergaria B-H, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res. August 2022;37(8):1437-1445.
2020	Cummings SR, Santora AC, Black DM, Russell RGG. History of alendronate. Bone. August 2020;137:115411.
2017	Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. NEJM. October 12, 2017;377(15):1417-1427.
2016	Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. NEJM. October 20, 2016;375(16):1532-1543.